Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) Cash & Equivalents (2016 - 2018)

Armata Pharmaceuticals' Cash & Equivalents history spans 6 years, with the latest figure at $13.4 million for Q3 2018.

  • For Q3 2018, Cash & Equivalents rose 73.37% year-over-year to $13.4 million; the TTM value through Sep 2018 reached $13.4 million, up 73.37%, while the annual FY2017 figure was $5.1 million, 0.0% changed from the prior year.
  • Cash & Equivalents for Q3 2018 was $13.4 million at Armata Pharmaceuticals, down from $15.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $16.6 million in Q1 2015 and bottomed at $2.2 million in Q1 2017.
  • The 5-year median for Cash & Equivalents is $8.6 million (2017), against an average of $9.5 million.
  • The largest YoY upside for Cash & Equivalents was 2185.81% in 2014 against a maximum downside of 67.67% in 2014.
  • A 5-year view of Cash & Equivalents shows it stood at $6.6 million in 2014, then surged by 78.35% to $11.7 million in 2015, then crashed by 56.28% to $5.1 million in 2016, then changed by 0.0% to $5.1 million in 2017, then surged by 160.97% to $13.4 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's Cash & Equivalents are $13.4 million (Q3 2018), $15.4 million (Q2 2018), and $8.2 million (Q1 2018).